Altre lingue Ardelyx, Inc.

Azioni

ARDX

US0396971071

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 13/01/2026			Variaz. 5gg	Var. 1 gen.
7,040 ^USD	-4,35%		+26,62%	+20,75%

09/01	ARDELYX, INC. : giudizio positivo di Piper Sandler	ZM
08/01	Ardelyx presenta i ricavi preliminari per il 2025 e illustra le prospettive strategiche per il 2026	RE

Altre lingue

12/01	North American Morning Briefing : Stock Futures Fall, Gold Hits Record on Fed Concerns -2-
08/01	Ardelyx reports preliminary 2025 revenue and provides 2026 strategic outlook
08/01	Ardelyx Provides 2026 Revenue Guidance for Ibsrela, Xphozah
08/01	Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
17/12	Ardelyx, Inc. Announces Executive Changes
25/11	Ardelyx Insider Sold Shares Worth $259,609, According to a Recent SEC Filing
07/11	Ardelyx Reports Xphozah Cuts Phosphate Levels in Dialysis Patients
07/11	Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
07/11	Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
07/11	Ardelyx, Inc. Presents Data, Including Results from the First Real-World Study of Xphozah
05/11	Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
05/11	Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
04/11	Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
31/10/25	Sector Update: Health Care Stocks Mixed Pre-Bell Friday
31/10/25	Ardelyx Q3 Breakeven, Revenue Increases; Shares Rise Pre-Bell
30/10/25	Earnings Flash (ARDX) Ardelyx, Inc. Reports Q3 Revenue $110.3M, vs. FactSet Est of $100.5M
30/10/25	Ardelyx: Q3 Earnings Snapshot
30/10/25	Ardelyx, Inc. Raises Earnings Guidance for the Year 2025
30/10/25	Biotech drug developer Ardelyx's Q3 product revenue rises 15%
30/10/25	Ardelyx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
30/10/25	Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
28/10/25	Ardelyx, Inc. Presents Data Supporting First-in-Class Retainagogue, IBSRELA at the American College of Gastroenterology's 2025 Annual Meeting
28/10/25	Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
22/10/25	Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week
21/10/25	Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Articoli MarketScreener Analisi MarketScreener Idee di trading

Altre lingue Ardelyx, Inc.

Azioni

ARDX

US0396971071

Biotecnologia

Altre lingue

Filtri